Literature DB >> 31612255

Upregulated CD200 in pre-retinal proliferative fibrovascular membranes of proliferative diabetic retinopathy patients and its correlation with vascular endothelial growth factor.

Yaguang Hu1, Anming Xie1, Qiaochu Cheng2.   

Abstract

OBJECTIVE AND
DESIGN: The objective was to determine the expression of CD200 in the pre-retinal proliferative fibrovascular membranes (PFVM) of patients with proliferative diabetic retinopathy (PDR) and to clarify its correlation with vascular endothelial growth factor (VEGF) and corresponding receptors.
METHODS: PFVM samples were collected by vitrectomy from 14 patients with PDR, and 11 non-diabetic patients who accepted vitrectomy for idiopathic epiretinal membranes removal. The expression of CD200, VEGF,VEGF-R1 and VEGF-R2 was measured via qPCR and immunofluorescent staining.
RESULTS: The mRNA level of CD200 was significantly higher in PDR patients than that in control patients. Meanwhile, CD200 and CD31 were found co-located and statistically associated in PFVM of PDR patients. The mRNA levels of VEGF, VEGF-R1 and VEGF-R2 were also significantly higher in PDR patients. Moreover, statistical association was found between CD200 and VEGF, VEGF-R1 in mRNA levels. But there was no significant correlationship between CD200 and VEGF-R2.
CONCLUSIONS: These results suggest a significantly increased expression of CD200 in PFVM of patients with PDR and present a crucial association between CD200 and VEGF-involved pathway. It represents a potential therapy that interfering with CD200 may inhibit the VEFG expression and neovascular formation in PDR patients.

Entities:  

Keywords:  CD200; Proliferative diabetic retinopathy; Proliferative fibrovascular membrane; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2019        PMID: 31612255     DOI: 10.1007/s00011-019-01290-4

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  41 in total

1.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200).

Authors:  R M Hoek; S R Ruuls; C A Murphy; G J Wright; R Goddard; S M Zurawski; B Blom; M E Homola; W J Streit; M H Brown; A N Barclay; J D Sedgwick
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 2.  Control of myeloid activity during retinal inflammation.

Authors:  Andrew D Dick; Debra Carter; Morag Robertson; Cathryn Broderick; Edward Hughes; John V Forrester; Janet Liversidge
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

3.  Vitreous levels of vascular endothelial growth factor-B in proliferative diabetic retinopathy.

Authors:  Satoshi Kinoshita; Kousuke Noda; Wataru Saito; Atsuhiro Kanda; Susumu Ishida
Journal:  Acta Ophthalmol       Date:  2016-01-30       Impact factor: 3.761

4.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

5.  mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging.

Authors:  Matthew G Frank; Ruth M Barrientos; Joseph C Biedenkapp; Jerry W Rudy; Linda R Watkins; Steven F Maier
Journal:  Neurobiol Aging       Date:  2006-05       Impact factor: 4.673

Review 6.  Molecular pathology of age-related macular degeneration.

Authors:  Xiaoyan Ding; Mrinali Patel; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2008-11-06       Impact factor: 21.198

Review 7.  Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review.

Authors:  Martin Gliem; Robert P Finger; Rolf Fimmers; Christian K Brinkmann; Frank G Holz; Peter Charbel Issa
Journal:  Retina       Date:  2013 Jul-Aug       Impact factor: 4.256

8.  Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ajmal Ahmad; Emilie Bittoun; Mohammad Mairaj Siddiquei; Ghulam Mohammad; Ahmed Mousa; Gert De Hertogh; Ghislain Opdenakker
Journal:  Acta Ophthalmol       Date:  2017-04-09       Impact factor: 3.761

9.  Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

Authors:  Gavin J Wright; Holly Cherwinski; Mildred Foster-Cuevas; Gary Brooke; Michael J Puklavec; Mike Bigler; Yaoli Song; Maria Jenmalm; Dan Gorman; Terri McClanahan; Man-Ru Liu; Marion H Brown; Jonathon D Sedgwick; Joseph H Phillips; A Neil Barclay
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

10.  CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization.

Authors:  Shintaro Horie; Scott J Robbie; Jian Liu; Wei-Kang Wu; Robin R Ali; James W Bainbridge; Lindsay B Nicholson; Manabu Mochizuki; Andrew D Dick; David A Copland
Journal:  Sci Rep       Date:  2013-10-30       Impact factor: 4.379

View more
  2 in total

1.  Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.

Authors:  Ze-Yu Liang; Yi-Peng Wang; Jing Li; Wen-Chao Yang; Yong-Fang Tu; Yue Zhang; Song Chen
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

2.  Increased vitreal levels of interleukin-10 in diabetic retinopathy: a Meta-analysis.

Authors:  Wei Tan; Jing-Ling Zou; Shigeo Yoshida; Bing Jiang; Ye-Di Zhou
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.